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Abstract 
Carnosine was originally discovered in skeletal muscle, where it exists in larger amounts than in 
other tissues. The majority of research into the physiological roles of carnosine have been 
conducted on skeletal muscle. Given this and the potential for muscle carnosine content to be 
increased with supplementation, there is now a large body of research examining the ergogenic 
effects (or otherwise) of carnosine.  More recent research, however, points towards a potential for 
carnosine to exert a wider range of physiological effects in other tissues, including the brain, heart, 
pancreas, kidney and cancer cells.  Taken together, this is suggestive of a potential for carnosine 
to have therapeutic benefits in health and disease, although this is by no means without 
complication.  Herein we will provide a review of the current literature relating to the potential 
therapeutic effects of carnosine in health and disease. 
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Introduction 
Carnosine, a histidine-containing dipeptide (HCD), is synthesised by bonding of the amino acids 
β-alanine and L-histidine, a reaction catalysed by carnosine synthase (Figure 1). Carnosine has 
been identified in vertebrates, including horses, greyhounds, camels and humans (see review by 
Boldyrev, Aldini, & Derave, 2013). Several animal species express other HCDs (anserine and 
ophidine/balenine), which are methylated forms of carnosine. Carnosine was, until recently, the 
only known HCD in human tissues, largely reported in skeletal and cardiac muscle, liver tissue, 
and regions of the central nervous system. Peters et al. (2015) showed, however, that anserine is 
also expressed in the renal cortex of human kidney, in concentrations approximately two times 
higher than those of carnosine.  
 
figure 1 near here 
 
Carnosine is considered an intracellular pH buffer, but several other physiological roles relevant 
to the function and homeostasis of different tissues have been proposed, including the regulation 
of Ca2+ transients in sarcoplasm and the sensitivity of skeletal muscle contractile apparatus to 
Ca2+, protection against reactive species, protection against glycation and inhibition of the 
formation of glycation-end products (Boldyrev et al., 2013). These properties are attracting 
attention relating to its potential ability to improve normal function, prevent ageing and help treat 
conditions in which glycation and oxidative stress play critical roles (e.g., diabetes and 
neurodegenerative diseases). Due to the physiological properties of carnosine associated with 
anti-proliferation (Shen et al., 2014), and its ability to act as a neurotransmitter (Tiedje, Stevens, 
Barnes, &Weaver, 2010), the potential for carnosine to act as an anti-cancer agent and to improve 
cognitive function has also been examined. Furthermore, it has been suggested that carnosine may 
not display the same functions in different tissues, and may even fulfil several functions within 
one tissue (Boldyrev et al., 2013). 
 
In humans, increasing the availability of free β-alanine, either via dietary (e.g., beef, chicken, 
pork, turkey and fish) or supplemental sources (either β-alanine or carnosine), results in increased 
skeletal muscle carnosine content (Harris et al., 2006). The relationship between β-alanine intake 
and skeletal muscle carnosine content occurs in a dose dependent manner (Stellingwerff et al., 
2012). Nonetheless, it remains uncertain how carnosine concentrations are regulated in other 
tissues. Although β-alanine and carnosine supplementation have been gaining attention due to a 
robust body of evidence to support their ergogenic effects (Saunders et al., 2017), there is also 
great potential for application in health and disease. In this review, we will use current knowledge 
on carnosine and other HCDs to explore the potential impact of carnosine on tissue function, 
specifically regarding health and disease. We discussed the importance of HCDs to healthy ageing 
as well as potential clinical applications in conditions such as neurodegenerative diseases, 
diabetes, kidney failure and cancer. However, the multiple roles played by HCDs in multiple 
organs and tissues imply that their applications extend to a number of other conditions that cannot 
be thoroughly discussed in a brief review. We advise the reader that there are other potential 
applications that will not be covered in this review, such as autism, schizophrenia, stroke, heart 
failure, circulatory disorders, wound healing, sepsis and cataracts.  
 
Carnosine in health  
Ageing  
Ageing is a multifactorial process, resulting from several persistent deleterious effects that 
negatively alter cellular and organism homeostasis. McFarland and Holliday (1994; 1999) 
suggested that carnosine could act as an anti-ageing agent, with improvements to the Hayflick 
limit (the maximum number of times cells can divide), and the apparent rejuvenation of senescent 
cells. Numerous possible anti-ageing outcomes of carnosine have been proposed, including; 
effects on reactive species (Kohen et al., 1988), inhibitory effects on glycolysis in tumour cells 
(Iovine et al., 2012), stimulatory effects on mitochondrial activity (Renner et al. 2010a), reduced 
toxic metabolite and methylglyoxal formation (Hipkiss et al., 1995), reduction of translation 
initiation factor phosphorylation, slowing translation, thus reducing error-protein generation (Son 
et al., 2008), and slowed telomere shortening (Shao, Li & Tan, 2004). Although these findings 
are promising, current evidence is mostly limited to in-vitro and cultured cell models, with little 
being known about the physiological relevance of these properties. It also remains unclear exactly 
how carnosine can affect cellular lifespan and the onset of age-related changes in tissue function.  
 
Studies in humans (Tallon et al., 2007) and animals (Johnson & Hammer, 1992) suggest that 
skeletal muscle carnosine content declines with ageing. Emerging evidence from human studies 
shows improvements in exercise performance following β-alanine supplementation in older adults 
(Stout et al., 2008; del Favero et al., 2012). β-alanine supplementation in older adults increases 
skeletal muscle carnosine content (+85%; del Favero et al., 2012), with responsiveness to 
supplementation occurring in a similar manner to younger individuals (Stellingwerff et al., 2012). 
In older adults, increased skeletal muscle carnosine was accompanied by improved exercise 
tolerance in constant-load submaximal and incremental tests (del Favero et al., 2012). β-alanine 
supplementation has also been shown to delay the onset of neuromuscular fatigue in older adults 
(Stout et al., 2008), with performance improvements being two-fold greater than those achieved 
by younger individuals (Stout et al., 2006). Although increased exercise tolerance and delayed 
fatigue may suggest that muscle function and quality of life could be improved, measures 
associated with skeletal muscle function (e.g., timed-stands, timed-up-and-go, and hand-grip 
strength) and quality of life have remained unaffected by increased skeletal muscle carnosine 
concentrations (del Favero et al., 2012). This might be due to the low sensitivity of these tests, 
limited by a “ceiling effect” in healthy populations. Thus, alterations to functional and health 
related measures may be more apparent in frail individuals, or those with more substantial 
impairments in physical function, which was not the case in the assessed population (del Favero 
et al., 2012). It remains plausible, therefore, that increased muscle carnosine content may be able 
to improve skeletal muscle function and improve mobility of older individuals; in turn reducing 
functional decline and risk of disability. Although more evidence is needed, these data imply that 
increasing skeletal muscle carnosine concentrations in older adults may result in improved muscle 
performance, alongside reducing the negative impact of ageing, albeit these effects may occur 
indirectly.  
 
Cognitive Function 
Carnosine synthase, an enzyme present in the human skeletal muscle, has been reported 
in different areas of the mammalian brain (Murakmai & Furuse, 2010). As well as carnosine, this 
ATP-dependent enzyme can synthesise homocarnosine, although this occurs at a lower efficiency. 
Carnosine is likely to be taken up into brain regions following its release from glial cells, since 
neurons, mainly those of the olfactory bulb (where carnosine is in greater concentrations), are 
unable to synthesise carnosine (Bellia, 2014). β-alanine can be rapidly transported into the brain, 
with research in rodents demonstrating increased carnosine content in the cerebral cortex and 
hypothalamus following β-alanine supplementation (Murakmai & Furuse, 2010). In-vitro studies 
with isolated human retina showed that β-alanine can be transported into and can accumulate in 
neuronal cells (Bruun & Ehinger, 1974). It is unclear, however, whether brain carnosine can be 
increased with β-alanine supplementation and, if so, in what regions this would occur. An in-vivo 
study assessing the effects of β-alanine supplementation on brain carnosine in humans has shown 
no increase in carnosine in the posterior cingulate cortex following four-weeks of β-alanine 
supplementation (Solis et al., 2015). Notably, the posterior cingulate cortex is highly-active and 
fulfils various functions, such as memory, focus of attention, processing and learning. It must be 
noted, however, that there are limitations in non-invasive quantification of carnosine in the human 
brain, such as the inability to distinguish carnosine from homocarnosine signals. It remains 
unknown whether other areas can benefit from β-alanine supplementation. 
 
Since the identification of HCDs in the brain, it has been proposed that increasing their 
availability could alter cognitive function and/or neuropsychological measures. In rodents 
experiencing stressful conditions, increased brain carnosine content achieved via β-alanine 
supplementation resulted in improvements to time in the maze (Murakmai & Furuse, 2010), an 
indicator of learning and memory. In humans, examination of functional MRI and 
neuropsychological assessments was undertaken to examine the effect of daily doses of carnosine 
and anserine over a three-month supplementation period in middle-aged and older individuals 
(Rokicki et al., 2015). Improvements in verbal episodic memory performance and decreased 
connectivity in the default mode network were reported following supplementation. These 
enhancements in cognitive function are in-line with earlier research in a similar elderly 
population, during which dietary anserine and carnosine supplementation significantly increased 
mean values of the Short Test of Mental Status; specifically, sub-scores of construction/copying, 
abstraction and recall (Szesniak, Budzen, Kopec, & Rymaszewska, 2014). 
 
The effects of β-alanine supplementation and the purported increased levels of HCDs in 
the brain on cognitive function in healthy individuals have been investigated; the results, however, 
are conflicting. A two-part investigation was the first to examine the effects of β-alanine 
supplementation on brain homocarnosine/carnosine signal in humans, and the mediating effects 
of β-alanine supplementation on the acute effect of exercise on cognitive function (Solis et al., 
2015). Following four-weeks of β-alanine supplementation there were no reported changes in the 
brain homocarnosine/carnosine signal in either vegetarian or omnivorous individuals, nor were 
there any effects of β-alanine supplementation on cognitive function at rest or following exercise. 
Similar responses were reported following four-weeks of β-alanine supplementation in military 
personnel, with enhanced vertical jump relative peak power, marksmanship and target 
engagement speed compared to placebo, but no impact on cognitive function (Hoffman et al., 
2014). It should be noted, that muscle and brain carnosine concentrations were not determined 
following supplementation. The experience of both physiological and psychological decline is 
not uncommon in military personnel undertaking prolonged, high-intensity military training, 
simulated combat exercise or military duties. As such, the Hoffman et al., (2015a) examined the 
effect of β-alanine supplementation on gastrocnemius muscle and brain carnosine content, 
physiological (2.5-km run, a 1-min sprint, 50-m casualty carry, repeated 30-m sprints with target 
shooting) and cognitive function (2-min serial subtraction test) measures in military personnel 
experiencing stressful conditions (active firing was taking place). Thirty-days of β-alanine 
supplementation significantly elevated muscle carnosine content, and improved both 
physiological performance (simulating a 50-m casualty carry) and cognitive function (2-min 
serial subtraction test) compared to placebo (Hoffman et al., 2015a). There was no detectable 
change in brain carnosine content following β-alanine supplementation, meaning that the 
underlying mechanism for improved cognitive function remains unclear.  
 
The manner in which the subtraction test (cognitive performance) was conducted could 
explain differences in these data, since active firing was taking place, which, when coupled with 
the stress of the test, may have contributed to participants experiencing high levels of anxiety. 
Later research in a murine model investigated the effects of 100 mg.kg-1 β-alanine 
supplementation for 30-days on brain carnosine concentrations and behavioural and 
neuroendocrine responses in a model of post-traumatic stress disorder (PTSD; Hoffman et al., 
2015b). Animals supplemented with β-alanine and exposed to predator-scent stress had 
significantly greater carnosine concentrations in the hippocampus, cortex, hypothalamus, 
amygdala and thalamus sections of the brain than animals that were provided with a normal diet, 
before exposure to the stressor. A 19% lower startle response in the acoustic startle response test 
and 15% lower freezing behaviour upon cue-exposure was reported. These data suggest that β-
alanine supplementation is able to attenuate some of the behaviours associated with experiencing 
high levels of stress and/or anxiety. To explore the potential mechanisms of these data, brain-
derived neurotrophic factor (BDNF), a key factor in the neuronal remodelling and potential 
modulator of synaptic plasticity and neurotransmitter release was examined. The animals 
experiencing predator-scent stress and β-alanine supplementation expressed greater BDNF 
compared to those exposed to stress and fed the control diet (Hoffman et al. 2015b). The authors 
speculated that the reduction in PTSD behaviours may be mediated by the maintenance of BDNF 
levels in the hippocampus during stress and/or anxiety. Overall, the current body of research 
highlights the potential ability of β-alanine supplementation to alter cognitive function and/or 
psycho-neurological measures; although the stressfulness of the environment and anxiety levels 
of the individual may be critical in mediating this interaction.  
 Carnosine in disease 
Neurodegenerative Diseases 
Alzheimer’s and Parkinson’s diseases are two of the most common neurodegenerative diseases, 
both characterised by mitochondrial energy dysfunction that ultimately leads to increased 
oxidative stress, chronic inflammation, and exacerbation of the ubiquitin-proteassome system; 
progressive loss of cellular function and neuronal cell death is a common endpoint of these 
diseases.  
 
In Alzheimer’s disease, carnosine inhibits the toxic effects of β-amyloid accumulation in cultured 
neuronal cells (Preston, Hipkiss, Himsworth, Romero, & Abbott, 1998); furthermore, carnosine 
can inhibit protein crosslinking and aggregation – two of the most extensive molecular features 
of Alzheimer’s pathogeny – mediated by glycation end-products (AGEs) (Corona et al., 2011). 
Using transgenic mouse models of Alzheimer’s disease, which expresses both β-amyloid and tau-
dependent pathologies, Corona et al. (2011) showed that carnosine supplementation reduced the 
accumulation of β-amyloid and suppressed mitochondrial dysfunction. Using a similar murine 
model, oral carnosine supplementation was effective in preventing cognitive decline (i.e., 
contextual memory assessed in a fear conditioning experiment), which was attributed to the ability 
of carnosine to inhibit the polymerisation of β-amyloid protein (Herculano et al., 2013).  
 
Inadequate blood flow to the brain occurs in Alzheimer’s disease; mediated by microvascular 
defects in brain blood vessels and accompanied by impaired clearance of neurotoxins. In healthy 
elderly humans, Hisatsune et al. (2016) showed that supplementation with a formulae containing 
anserine:carnosine (3:1, 1 g/day for 3 months) counteracted the decline in blood flow in the 
posterior cingulate cortex associated with ageing, providing confirmatory evidence of the ability 
of HCDs to improve cerebral blood flow. Importantly, better preservation of memory in healthy 
elderly individuals was also reported. Similar results were shown in a murine model of 
Alzheimer’s disease (Kaneko, Enya, Enomoto, Ding, & Hisatsune 2017). Eight-weeks of anserine 
supplementation improved memory impairment in the Morris water maze and contextual fear 
conditioning tests. Moreover, anserine resulted in supressed glial inflammatory reactions in the 
hippocampus and increased pericytes coverage in brain capillaries – an indicator of 
neurovascular-unit function (Kaneko et al., 2017). No effects of anserine were, however, shown 
on β-amyloid plaques. In light of this evidence, carnosine has been postulated to control the 
progression of Alzheimer’s disease; clinical studies, however, are yet to be conducted to assess 
the relevance of carnosine-based therapies on Alzheimer’s disease progression. 
 
In Parkinson’s disease, Boldyrev et al. (2008) enrolled 36 patients in an open-label clinical trial 
to receive DOPA (dihidroxyphenilalanine) or DOPA+carnosine (1.5 g/day) for 30-days. The 
patients treated with DOPA+carnosine presented with a significantly better (+36%) clinical 
improvement, as assessed by the Unified Parkinson’s Disease Rating Scale, in comparison with 
the conventional treatment alone (+16%). Larger improvements in physical symptoms, such as 
rigidity and tremors in the upper body extremities, were also reported, accompanied by increased 
activity of Cu/Zn-superoxide dismutase in red blood cells and decreased protein carbonyls and 
lipid hydroperoxides in plasma. Although these promising results suggest that carnosine could 
potentiate the effects of conventional treatments, no further evidence is available relating to the 
therapeutic effects of carnosine in Parkinson’s disease. Future studies should confirm the clinical 
relevance of carnosine as an adjuvant treatment for Parkinson’s disease, as well the underpinning 
mechanisms. 
 
Type II diabetes  
Type II diabetes and its complications are amongst the most common causes of morbidity and 
mortality in Western societies. Diabetes complications are multifactorial, but the long-term 
accumulated cellular damage caused by the formation of AGEs likely play a central role. AGEs 
are generated during chronic hyperglycaemia and are related to increased formation of free-
radicals and protein crosslinks, thus inducing oxidative stress, morphofunctional alterations of 
cells and extracellular matrices and systemic low-grade inflammation. 
 Animal models of diabetes have shown diminished carnosine in plasma, retina, liver and kidneys 
in both type I and type II diabetes (Sauerhofer et al., 2007). In humans, studies have been limited 
to the analysis of carnosine in the skeletal muscle and results are equivocal. A cross-sectional 
study has shown that patients with type II, but not type I, diabetes have 45% less muscle carnosine 
in comparison with healthy controls (Gualano et al., 2012). This reduction was attributed to 
carnosine being consumed by AGEs and free radicals, which are both hallmarks of insulin 
resistance, although such assertions need confirmation. Cripps et al. (2017) reported that 
carnosine is an effective scavenger of reactive oxygen and nitrogen species, resulting in a 
doubling of insulin secretion from isolated mouse islets and INS-1 β-cells. In addition, carnosine 
also reversed glucolipotoxic inhibition of insulin secretion and enhanced glucose uptake into 
C2C12 skeletal muscle cells. 
 
The recent identification of adducts of carnosine with by-products of aldehyde detoxification 
(e.g., acrolein) suggests that carnosine may be consumed by sub-products linked with the 
pathogenesis of diabetes complications, such as exacerbated lipoxidation (Bispo et al., 2016). 
Contrary to evidence that carnosine may be reduced in type II diabetes due to its ability to entrap 
toxic sub-products, Stegen et al. (2015) reported higher intramuscular carnosine concentrations 
in individuals classified as pre-diabetic (+30%) and type II diabetic (+39%) in comparison with 
lean controls. This finding was possibly not related to insulin resistance per se, but perhaps to a 
higher distribution of type II fibres in these individuals. This, however, was not directly 
determined in the study. Alternatively, the authors speculated that increased carnosine could be a 
result of a compensatory mechanism that would take place when carnosine is consumed at high 
rates by elevated oxidative stress, carbonyl stress, excessive glycation and aldehyde 
detoxification. 
 
Due to these properties, carnosine has been considered to play a clinically significant role in 
diabetes treatment, especially in preventing diabetic complications. Although evidence is still 
emerging, both animal (Lee et al., 2005) and human (Janssen et al., 2005) studies have indicated 
the potential of carnosine to delay diabetes progression. Carnosine supplementation is capable of 
improving glycaemic control and reducing glycated haemoglobin in a murine model of type II 
diabetes (Sauerhofer et al., 2007). Similar results were shown in obese mice that developed 
diabetes; 18-weeks of carnosine supplementation reduced glycaemia, improved glycaemic control 
and preserved the integrity of the kidney (Albrecht et al. 2017). In-line with these findings, in 
obese Zucker rats, 24-weeks of carnosine supplementation blunted the development of 
dyslipidaemia and hypertension, whilst preventing damage to the kidney (Aldini et al. 2011). 
Furthermore, carnosine supplementation counteracted the deterioration of kidney function, blood 
lipid profiles, insulin secretion and insulin resistance. More evidence from animal studies suggests 
that the mechanisms of carnosine protection may also involve decreased apoptosis of glomerular 
cells (Peters et al., 2014) or normalisation of vascular permeability (Peters et al., 2012) 
 
In humans, early evidence of the protective effects of carnosine on diabetes progression and 
complications came from association studies with patients carrying polymorphisms on the genes 
encoding for serum and tissue carnosinases (i.e., CNDP1 and CNDP2). These genes are adjacently 
located in the 18q chromosome, a locus that has been previously linked to diabetic nephropathy 
(Vardarli et al., 2002). One particular polymorphism on exon 2 of the CNDP1 gene seems to be 
the one most associated with diabetic complications (Janssen et al., 2005); this polymorphism 
consists of different repeats of trinucleotides resulting in a different number of leucine repeats 
that vary from five to seven. In fact, several different polymorphisms leading to a different number 
of leucine-repeats have been described, with shorter repeats being associated with lower plasma 
carnosinase activity and longer repeats with higher plasma carnosinase activities (Janssen et al., 
2005). Accordingly, patients with the short repeat alleles tended to be more protected against 
diabetic nephropathy, suggesting that carnosine may play a protective role in diabetes (Janssen et 
al., 2005). Similar results were confirmed in other (Freedman et al., 2007), but not all (Wanic et 
al., 2008) studies. 
 
Clinical studies with carnosine supplementation are scarce, but emerging evidence appears to 
confirm some of the theoretical mechanisms of action, particularly those related to carbonyl 
species quenching (Bispo et al., 2016). A pilot clinical trial provided evidence of the ability of 
carnosine supplementation to protect against diabetes development in non-diabetic obese 
individuals (de Courten et al., 2016). Overweight and obese adults were randomly allocated to 
ingest carnosine (2 g/day) or a placebo for 12-weeks. An increase in fasting insulin and insulin 
resistance was reported with placebo, but not carnosine. The group receiving carnosine also had 
improved responses to an oral glucose test (i.e., lower glucose and insulin), which was only shown 
in a subgroup of individuals with impaired glucose tolerance. Such findings, although promising, 
require further confirmation.  
 
  
Acute kidney failure  
Acute kidney failure is defined as a sudden, sustained impairment of kidney function, typically 
for periods of 1-7 days, resulting in reduced glomerular filtration rate, urinary volume, electrolyte 
imbalance and impaired pH regulation. Kidney damage induced by ischemia/reperfusion is a key-
factor involved in the pathogenesis of acute kidney failure and it is commonly observed in various 
clinical conditions, such as recovery from cardiac arrest, kidney transplantation and partial 
nephrectomy (Thadhani, Pascual, & Bonventre, 1996). Acute kidney failure may also result in 
acute tubular necrosis and increased renal vascular resistance (Thadhani et al., 1996), thereby 
being typically accompanied by impaired renal blood flow (Basile et al., 2012). Although the 
molecular mechanisms underpinning these responses are not fully elucidated, ATP depletion, 
oxidative damage, phospholipase activation, neutrophil infiltration and exacerbation of 
adrenergic activation have been shown to play a central role in the pathogenesis of acute kidney 
failure (Basile et al., 2012). Any substance capable of suppressing or attenuating any of the 
processes involved in its pathogenesis may, therefore, be protective during episodes of acute 
failure (Fuji et al., 2003), thus reducing the area of the kidney where cells suffer lethal injuries.  
Reducing lethal injuries to the point of non-lethality is critical for recovery and regeneration 
(Basile et al., 2012).  
 
In this respect, carnosine may have a protective effect, as suggested by Kurata et al. (2006) using 
an animal model of acute kidney failure induced by ischaemia/reperfusion. Intra-
cerebroventricular injection of carnosine before acute kidney failure suppressed the increase in 
adrenergic activity in the renal sympathetic nerves, which was paralleled by attenuation in kidney 
dysfunction. Interestingly, no effect of N-alpha-Acetyl-l-carnosine (a carnosine analogue resistant 
to carnosinases) was observed, whereas the injection of L-histidine resulted in similar protective 
effects to those of carnosine. Thus, the mechanism of protection may involve the activation of 
Histamine H3 receptors in the central nervous system, which was confirmed by the infusion of 
thioperamide (a histamine receptor antagonist) that eliminated the protective effects of carnosine 
(Kurata et al., 2006). Similar findings were shown in a rat model of acute kidney failure (Fujii et 
al., 2003), which further expanded the evidence that carnosine ameliorates adrenergic activation 
by reducing epinephrine release from the kidneys in animals treated with carnosine. The results 
by Kurata et al. (2006) and Fijii et al. (2003) indicate a protective role of carnosine that is 
independent of antioxidant activity, although oxidative stress is critically involved in the 
pathogenesis of acute kidney damage. There remains, therefore, an unexplored potential for 
carnosine to protect the kidneys and preserve function in acute episodes. Evidence from studies 
in humans, however, are still absent.  
 
Cancer 
The potential for carnosine to exert anti-neoplastic effects was first proposed by Nagai and Suda 
(1986) who implanted sarcoma-180 tumour cells under the skin of mice. Carnosine, β-alanine and 
a saline control were administered subcutaneously 24-h later in close proximity to the tumour 
implantation site, with administration continuing on every other day. Administration with both β-
alanine and carnosine reduced tumour growth and reduced mortality, compared to those treated 
with carnosine alone.  
 Despite these encouraging findings, work in this area did not gain much momentum until 10-years 
later when Holiday and McFarland (1996) showed that 20mM of carnosine was able to selectively 
inhibit the growth of transformed and neoplastic cells. Subsequently, much of the work in this 
area has stemmed from the laboratory of Frank Gaunitz (University of Leipzig), whose group has 
performed a series of experiments showing positive effects of carnosine on reducing the growth 
of human glioblastoma cells (Renner et al., 2008) and in reducing the growth and size of tumours 
implanted subcutaneously in nude mice (a strain with no or poor functioning thymus that results 
in reduced T cell production and an impaired immune system, Renner et al., 2010b). In the latter 
study, Renner et al. (2010b) subcutaneously implanted NIH3T3 fibroblasts in mice, which 
continually express human epidermal growth factor receptor 2 in two independent experiments. 
The mice in both studies then received daily intraperitoneal injections of 500µL of a 1M carnosine 
solution, with treated mice being compared to control mice receiving intraperitoneal injections of 
sodium chloride. Although carnosine was not able to completely reverse tumour growth and 
development in this study, the aggressive growth of the tumour was delayed in comparison with 
controls in both experiments. Interestingly, microscopic examination of the tumours indicated 
that there were a lower number of mitoses per high-powered field when compared with untreated 
mice, suggesting a direct anti proliferative action of carnosine in-vivo. These encouraging studies 
demonstrating the anti-proliferative effects of carnosine on models of glioblastoma (a highly 
aggressive form of brain cancer that can be very difficult to treat) have been extended to other 
cancer cell lines, including those from the colon (Iovine et al., 2012), gut (Shen et al., 2014) and 
ovaries (Mikula-Pietrasik & Ksiazek, 2016), showing that evidence is gathering in support of 
direct anti-tumour actions of carnosine. 
 
The effects of carnosine on tumour cells seem in direct contrast to the effects on other cell types, 
where carnosine has been shown to increase cell viability. It has been suggested that these 
apparent differences can be reconciled, however, by considering the different metabolic 
differences between cancer cells and other cells where carnosine is seemingly pro-proliferative 
(Gaunitz & Hipkiss, 2012). Most cells derive their energy from oxidative phosphorylation under 
normoxic conditions, whereas cancer cells have a high dependence on glycolysis (known as the 
Warburg effect) for their ATP production, which results in the production of lactate even in the 
presence of sufficient oxygen (Oppermann, Schanbel, Meixensberger, & Gaunitz, 2016). It has 
been suggested that the primary mechanism for the anti-neoplastic effects of carnosine relate to 
its ability to inhibit glycolysis (Renner et al., 2010a). Hipkiss and Gaunitz (2014) recently 
suggested that there are several possibilities to explain carnosine’s effects on glycolytic activity 
that, in turn, underpin the anti-neoplastic effects shown in cancer cells. These were reported to 
include effects on a) glycolytic enzymes, b) metabolic regulatory activities, c) redox biology, d) 
protein glycation, e) glyoxalase activity, f) apoptosis, g) gene expression and h) metastasis. 
Oppermann et al. (2016) provided some evidence in support of this, but also suggested that the 
anti-neoplastic effects of carnosine on glioblastoma cells are attenuated in the presence of higher 
pyruvate, which is independent of oxidative phosphorylation.  
 
Perspectives 
Although identified ~100 years ago, only in the last 30 years has research identified carnosine as 
a factor that might exert an influence on health and disease. Evidence is indicative of the ability 
of the carnosine to influence health and disease status, most clearly in the skeletal muscle and 
brain at this stage. Many of these developments are, however, recent and numerous important 
questions remain unanswered, particularly with regards to the precise mechanisms by which 
carnosine acts and the real impact of carnosine on both health and disease status. More 
mechanistic approaches, such as knocking-out genes that control carnosine content in tissues (e.g., 
carnosine synthase and tissue carnosinase) could be used, as well super-expressing them. 
Alternative approaches to gather further knowledge on the physiological roles of carnosine may 
comprise comparative physiology studies. Further studies should explore whether these properties 
are physiologically relevant to cellular and tissue functions and whether they can be translated 
into therapeutic benefits, especially in diseases where small-scale clinical studies have shown 
promising results, such as diabetes. Large-scale clinical studies are indeed necessary to provide 
stronger evidence on the actual clinical benefits of interventions to increase carnosine levels on 
primary and secondary disease prevention, as well as treatment. Future studies should also look 
at improving previous clinical research by using large sample sizes, long follow-up periods and 
measures that link the biological actions of carnosine to their clinical effects. Effective ways to 
apply the therapeutic effects of increased carnosine levels in different human tissues must also be 
more clearly established, since the lower bioavailability of carnosine may impose significant 
limitations to supplementation strategies involving the intact dipeptide. Alternative strategies, 
such as the use of carnosine-analogues or anserine, both resistant to carnosinases, should also be 
explored in the future. Whether or not β-alanine supplementation can increase carnosine 
concentrations in tissues other than skeletal muscle remains unknown and should, therefore, be 
explored. Finally, increased carnosine in muscle in response to exercise may be a novel long-term 
adaptation to exercise training that might explain some of benefits of exercise to health – this 
novel possibility could also be explored in future studies. 
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Figure caption: 
Figure 1: Endogenous synthesis of carnosine by the enzyme carnosine synthase. The molecular masses of 
the three compounds (carnosine: 226 g.mol-1; L-histidine: 155 g.mol-1; β-alanine: 89 g.mol-1) indicates a 
loss of 18 g.mol-1 during carnosine formation, which is consistent with the loss of one water molecule. 
 
